SK Bioscience Renews Turkey GMP Certification for Andong L House

SK Bioscience 'L House Vaccine Center' in Andong-si, Gyeongbuk (Photo by SK Bioscience)

[Asia Economy Reporter Chunhee Lee] SK Bioscience is accelerating the global expansion of its self-developed vaccines by consecutively obtaining and renewing Good Manufacturing Practice (GMP) certifications from various countries around the world.

On the 4th, SK Bioscience announced that the vaccine production facilities, processes, and quality systems at the L House in Andong, Gyeongbuk, have renewed their GMP certification from the Turkish Medicines and Medical Devices Agency (TITCK). Currently, the Andong L House manufactures SK Bioscience's self-developed vaccines, including ▲Skycellflu trivalent and quadrivalent (influenza vaccines) ▲Skyvaricella (chickenpox vaccine) ▲Skyzoster (shingles vaccine).

With this, SK Bioscience has established a foundation to supply its self-developed vaccines to Turkey, the second-largest market in Eastern Europe. Turkey, with a population of approximately 85.56 million, relies on imports for more than 70% of its pharmaceuticals. Securing Turkish GMP certification is essential for market entry.

Previously, in May 2019, SK Bioscience was the first to obtain Turkish GMP certification for the vaccine manufacturing facilities within the L House. Ahead of the certification's expiration earlier this month, SK Bioscience successfully renewed it through processes including document review. Based on this certification, SK Bioscience plans to accelerate exports of four vaccines to Turkey, including participating in the Turkish government's international tender for chickenpox vaccines, and further expand into European and Asian markets.

SK Bioscience has recently acquired additional EU-GMP certification from the European Medicines Agency (EMA) and continues to obtain GMP certifications from major countries worldwide. By 2024, the company plans to invest 200 billion KRW in the L House to expand manufacturing facilities and build new platform facilities such as messenger RNA (mRNA) and next-generation viral vectors, thereby enhancing production capacity.

Jae-yong Ahn, President of SK Bioscience, stated, “The L House has consistently obtained various international certifications even among leading global bio companies, proving its independent technological capabilities and development and production capacities. Based on the trust built in the global market through COVID-19, we will continuously collaborate with various global companies to gradually increase our market influence.”

This content was produced with the assistance of AI translation services.